Features of interpretation of the results of studies of ABО and Rhesus antigens and antibodies in patients with hematological diseases
Irina I. Krobinets, Natalya V. Mineeva, Elena A. Sysoeva, Alexander V. Chechetkin
Russian Research Institute of Hematology and Transfusiology FMBA, Saint-Petersburg, Russia
transfusion_spb@mail.ru
Keywords: лимфопролиферативные заболевания, миелопролиферативные неоплазии, АВО, Rh, двойная популяция эритроцитов, потеря экспрессии антигенов, lymphoproliferative disorders, myeloproliferative neoplasms, АВО, Rh, double populations of red blood cells, loss of antigen expression
Abstract
Aim. To assess the aspects
of interpretation of pre-transfusion tests in patients with
hematological diseases. Material and Methods. We performed an analysis
of the results of serological studies of ABО, Rh blood groups in blood
samples of 857 patients with oncohematological diseases. ABO blood group
determination and typing of D, C, c, E, e, К antigens were carried out
using a gel agglutination test. Results. The decrease in strength of the
agglutination of standard red blood cells by the patient’s anti-A
and/or anti-B antibodies was observed in 112 patients (13.07% of the
total number of patients). Abnormal agglutination strength in ABO and Rh
antigens testing was observed in 17 patients (1.98% of the total number
of patients), among them were 7 patients with acute myeloid leukemia
(AML), 6 - with сhronic myeloid leukemia (CML), 2 - myelodysplastic
syndrome (MDS), 2 - polycythemia vera (PV). Double populations of red
blood cells were mainly detected in patients with MDS (45.61 %),
aplastic anemia (AA) (27.27 %), primary myelofibrosis (PMF) (22.73 %),
acute leukemia (AL) (22.2 %). In most cases double populations were
associated with previous transfusions of blood products, meanwhile,
three patients from this group (two patients with CML and one patient
with PV) had never received blood transfusions before. Conclusion.
Differences in anti-A and anti-B antibodies content were much more
common in patients with lymphoproliferative disorders (LPDs) than in
patients with myeloproliferative neoplasms (MPNs) (85.71% and 8.04%,
respectively), while decrease of expression of red blood cell antigens
was more typical for MPNs and did not occur in patients with LPDs.
|
